The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
Open accessAbstract
BACKGROUND: Data are lacking on whether lenalidomide maintenance therapy prolongs the time to disease progression after autologous hematopoietic stem-cell transplantation in patients with multiple myeloma. METHODS: Between April 2005 and July 2009, we randomly assigned 460 patients who were younger than 71 years of age and had stable disease or a marginal, partial, or complete response 100 days after undergoing stem-cell transplantation to lenalidomide or placebo, which was administered until disease progression. The starting dose of lenalidomide was 10 mg per day (range, 5 to 15). RESULTS: The study-drug assignments were unblinded in 2009, when a planned interim analysis showed a significantly longer time to disease progression in the lenalidomide group. At unblinding, 20% of patients who received lenalidomide and 44% of patients who received placebo had progressive disease or had died (P<0.001); of the remaining 128 patients who received placebo and who did not have progressive disease, 86 crossed over to lenalidomide. At a median follow-up of 34 months, 86 of 231 patients who received lenalidomide (37%) and 132 of 229 patients who received placebo (58%) had disease progression or had died. The median time to progression was 46 months in the lenalidomide group and 27 months in the placebo group (P<0.001). A total of 35 patients who received lenalidomide (15%) and 53 patients who received placebo (23%) died (P=0.03). More grade 3 or 4 hematologic adverse events and grade 3 nonhematologic adverse events occurred in patients who received lenalidomide (P<0.001 for both comparisons). Second primary cancers occurred in 18 patients who received lenalidomide (8%) and 6 patients who received placebo (3%). CONCLUSIONS: Lenalidomide maintenance therapy, initiated at day 100 after hematopoietic stem-cell transplantation, was associated with more toxicity and second cancers but a significantly longer time to disease progression and significantly improved overall survival among patients with myeloma. (Funded by the National Cancer Institute; ClinicalTrials.gov number, NCT00114101.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Lenalidomide is the standard of care for maintenance therapy for most patients.142–147”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [143]
Experimental — accuracy not yet measuredIn the citing paper
“Patients who have disease progression while not on treatment with lenalidomide can often be re-treated effectively with this agent37,38, sometimes multiple times, and typically in combination with proteasome inhibitors such as carfilzomib39 and ixazomib40 or with daratumumab41.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Cox, D. R., & Oakes, D. (2018) · Chapman & Hall/CRC eBooks · doi:10.1201/9781315137438 · Cited by 6,269
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,957
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citationPalumbo, A. P., & Anderson, K. C. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,382
Self-citationThe Statistical Analysis of Failure Time Data
Klein, J. P., Kalbfleisch, J. D., & Prentice, R. L. (1982) · Technometrics · doi:10.1080/00401706.1982.10487769 · Cited by 2,248
Improved survival in multiple myeloma and the impact of novel therapies
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A. A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2007) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,241
Raje, N. S., & Anderson, K. C. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0017-x · Cited by 2,164
Self-citation
Flagged first, then by citations
Research works printed but not linked: 2
- 10.1001/archinte.135.1.147 · DOI
- 10.2307/2281868 · DOI · Paper page
Cited by
Sorted by citations
Items 301–400 of 1,000
Should Overall Survival Remain an Endpoint for Multiple Myeloma Trials?
Holstein, S. A., Suman, V. J., & McCarthy, P. L. (2019) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-019-0495-9 · Cited by 29
Self-citationMerz, M., Dechow, T. N., Scheytt, M., Schmidt, C., Hackanson, B., & Knop, S. T. (2020) · Annals of Hematology · doi:10.1007/s00277-020-04023-4 · Cited by 29
Shain, K. H., & Tao, J. (2013) · Oncogene · doi:10.1038/onc.2013.379 · Cited by 29
A review of the venous thrombotic issues associated with multiple myeloma
Fotiou, D., Gerotziafas, G., Kastritis, E., Dimopoulos, M. A., & Terpos, E. (2016) · Expert Review of Hematology · doi:10.1080/17474086.2016.1194750 · Cited by 29
Recent advances in multiple myeloma: a Korean perspective
Hong, J., & Lee, J. H. (2016) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2015.408 · Cited by 29
Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT
Syed, Y. Y. (2017) · Drugs · doi:10.1007/s40265-017-0795-0 · Cited by 29
Fixed duration vs continuous therapy in multiple myeloma
Ludwig, H., & Zojer, N. (2017) · Hematology · doi:10.1182/asheducation-2017.1.212 · Cited by 29
Therapeutic Advances in Relapsed or Refractory Multiple Myeloma
Anderson, K. C. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0199 · Cited by 28
Self-citationCurrent approaches for the treatment of multiple myeloma
Watanabe, R., Tokuhira, M., & Kizaki, M. (2013) · International Journal of Hematology · doi:10.1007/s12185-013-1294-z · Cited by 29
Multiple Myeloma : Recent Progress in Diagnosis and Treatment
Chou, T. (2012) · Journal of the Japan Society of the Reticuloendothelial System · doi:10.3960/jslrt.52.149 · Cited by 28
Mian, I., Milton, D. R., Shah, N. D., Nieto, Y. L., Popat, U., Kebriaei, P., Parmar, S., Oran, B., Shah, J. J., Manasanch, E. E., et al. (2016) · Cancer · doi:10.1002/cncr.30366 · Cited by 28
Self-citationAldoss, I. T., Capelletti, M., Park, J., Sklavenitis‐Pistofidis, R., Pillai, R. K., Stiller, T., Sanchez, J. F., Forman, S. J., Ghobrial, I. M., & Krishnan, A. Y. (2018) · Leukemia · doi:10.1038/s41375-018-0213-y · Cited by 28
Peña, C., Riva, E., Schutz, N. P., Tarin-Arzaga, L. C., Martínez‐Cordero, H., Bove, V., Osorio, R., Chandía, M., Beltrán, C., Schulz, J., et al. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1804558 · Cited by 28
Brown, S., Sherratt, D., Hinsley, S., Flanagan, L. M., Roberts, S., Walker, K., Hall, A., Pratt, G., Messiou, C., Jenner, M. W., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-046225 · Cited by 28
Li, H., Zhao, L., Sun, Z., Yao, Y., Li, L., Wang, J., Hua, T., Ji, S., Wang, S., Cheng, H., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1019548 · Cited by 29
Pandya, C. J., Hashmi, S. K., Khera, N., Gertz, M. A., Dispenzieri, A. A., Hogan, W. J., Siddiqui, M. A., Noyes, K., & Kumar, S. K. (2014) · Clinical Transplantation · doi:10.1111/ctr.12421 · Cited by 28
Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs
Gowda, L., Shah, M. V., Badar, I., Bashir, Q., Shah, N. D., Patel, K. K., Kanagal‐Shamanna, R., Mehta, R. S., Weber, D. M., Lee, H. C., et al. (2018) · Bone Marrow Transplantation · doi:10.1038/s41409-018-0392-1 · Cited by 28
Self-citationLi, A. Y., Atenafu, E. G., Bernard, R. S., Masih‐Khan, E., Reece, D. E., Franke, N., Tiedemann, R. E., Prica, A. A., Trudel, S., Kukreti, V., et al. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0697-8 · Cited by 28
Minimal Residual Disease Negativity Is a New End Point of Myeloma Therapy
Harousseau, J., & Avet‐Loiseau, H. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.1331 · Cited by 28
Kurtin, S. E., & Bilotti, E. (2013) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2013.4.5.11 · Cited by 27
Advancements in Nanomedicine for Multiple Myeloma
Detappe, A., Bustoros, M. W., Mouhieddine, T. H., & Ghoroghchian, P. P. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.04.005 · Cited by 27
ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment
Liu, J., Hideshima, T., Xing, L., Wang, S., Zhou, W., Samur, M., Sewastianik, T., Ogiya, D., An, G., Gao, S., et al. (2021) · Science Advances · doi:10.1126/sciadv.abg2697 · Cited by 27
Self-citationAilawadhi, S., Swaika, A., Razavi, P., Yang, D., & Chanan-Khan, A. A. (2014) · Blood Cancer Journal · doi:10.1038/bcj.2014.63 · Cited by 27
How lenalidomide is changing the treatment of patients with multiple myeloma
Dimopoulos, M. A., Terpos, E., & Niesvizky, R. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.05.013 · Cited by 28
Efficacy and Safety of Busulfan-Based Conditioning Regimens for Multiple Myeloma
Reece, D. E., Song, K., LeBlanc, R., Mezzi, K., Olujohungbe, A., White, D. J., Zaman, F., & Belch, A. R. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0384 · Cited by 27
Danhof, S., Schreder, M., Knop, S. T., Rasche, L., Strifler, S., Löffler, C., Gogishvili, T., Einsele, H., & Hudecek, M. (2017) · Haematologica · doi:10.3324/haematol.2017.178947 · Cited by 27
Ahmedzai, S. H., Snowden, J. A., Ashcroft, A. J., Cairns, D. A., Williams, C. D., Hockaday, A., Cavenagh, J. D., Ademokun, D., Tholouli, E., Allotey, D., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01006 · Cited by 27
Conticello, C., Romano, A., Fabro, V. D., Martino, E. A., Calafiore, V., Sapienza, G., Leotta, V., Parisi, M. S., Markovic, U., Garibaldi, B., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8060877 · Cited by 27
Wayne, A. S., Giralt, S., Kröger, N. M., & Bishop, M. R. (2013) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2013.08.016 · Cited by 27
Self-citationNew Approaches to Management of Multiple Myeloma
Genadieva-Stavric, S., Cavallo, F., & Palumbo, A. P. (2014) · Current Treatment Options in Oncology · doi:10.1007/s11864-014-0276-6 · Cited by 27
Myeloma: Classification and Risk Assessment
Fonseca, R., & Monge, J. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.07.002 · Cited by 26
Immunotherapeutic and Targeted Approaches in Multiple Myeloma
Nadeem, O., Tai, Y., & Anderson, K. C. (2020) · ImmunoTargets and Therapy · doi:10.2147/itt.s240886 · Cited by 26
Self-citationManasanch, E. E., Salem, D., Yuan, C. M., Tageja, N., Bhutani, M., Kwok, M., Kazandjian, D. G., Carter, G., Steinberg, S. M., Zuchlinski, D., et al. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.955020 · Cited by 26
Mechanisms of Resistance in Multiple Myeloma
Papadas, A., & Asimakopoulos, F. A. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_10 · Cited by 26
Managing multiple myeloma in elderly patients
Diamond, E., Lahoud, O. B., & Landau, H. J. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1365859 · Cited by 26
Self-citationCurrent Treatment for Multiple Myeloma
Avigan, D., & Rosenblatt, J. M. (2014) · New England Journal of Medicine · doi:10.1056/nejme1407442 · Cited by 26
Minimal Residual Disease-Adapted Therapy in Multiple Myeloma: Current Evidence and Opinions
Meseha, M., Hoffman, J. E., Kazandjian, D. G., Landgren, O., & Diamond, B. T. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01537-2 · Cited by 25
Current therapeutic strategies for multiple myeloma
Torimoto, Y., Shindo, M., Ikuta, K., & Kohgo, Y. (2015) · International Journal of Clinical Oncology · doi:10.1007/s10147-015-0826-3 · Cited by 25
Best Treatment Strategies in High-Risk Multiple Myeloma: Navigating a Gray Area
Bianchi, G., Richardson, P. G. G., & Anderson, K. C. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.7900 · Cited by 25
Self-citationParmar, S., Bookout, R., Shapiro, J., Tombleson, R. L., Perkins, J., Kim, J., Yue, B., Tomblyn, M., Alsina, M., & Nishihori, T. (2014) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.56 · Cited by 25
Iriuchishima, H., Ozaki, S., Konishi, J. S., Matsumoto, M., Murayama, K., Nakamura, F., Yamamoto, G., Handa, H., Saitoh, T., Nagura, E., et al. (2015) · Acta Haematologica · doi:10.1159/000439424 · Cited by 25
End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma
Hoering, A., Durie, B. G. M., Wang, H., & Crowley, J. J. (2017) · Future Oncology · doi:10.2217/fon-2016-0504 · Cited by 25
Tan, D. C. L., Lee, J. H., Chen, W.-M., Shimizu, K., Hou, J., Suzuki, K., Nawarawong, W., Huang, S., Chim, C. S., Kım, K., et al. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1427858 · Cited by 25
Yin, L., Wen, X., Lai, Q., Li, J., & Wang, X. (2018) · Oncology Letters · doi:10.3892/ol.2018.8120 · Cited by 25
Badar, T., Hari, P., Dávila, O., Fraser, R. A., Wirk, B. M., Dhakal, B., Freytes, C. O., Valdes, C. R., Lee, C., Vesole, D. H., et al. (2020) · Cancer · doi:10.1002/cncr.33208 · Cited by 25
Self-citationMusso, M., Messina, G., Marcacci, G., Crescimanno, A., Console, G., Donnarumma, D., Scalone, R., Pinto, A., & Martino, M. V. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.06.011 · Cited by 24
Hari, P., Mateos, M., Abonour, R., Knop, S. T., Bensinger, W., Ludwig, H., Song, K., Hájek, R., Moreau, P., Siegel, D. S. D., et al. (2017) · Leukemia · doi:10.1038/leu.2017.122 · Cited by 24
Self-citationPatel, P. R., Oh, A. L., Koshy, M., Sweiss, K. I., Saraf, S. L., Quigley, J. G., Khan, I., Mahmud, N., Hacker, E. D., Ozer, H., et al. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1390231 · Cited by 24
Rossmann, E. D., Österborg, A., Löfvenberg, E., Choudhury, A., Forssmann, U., von Heydebreck, A., Schröder, A., & Mellstedt, H. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.29918 · Cited by 24
Role of thalidomide in the treatment of patients with multiple myeloma
Morgan, G. J., & Davies, F. E. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.05.012 · Cited by 24
Updates to the guidelines for the diagnosis and management of multiple myeloma
Pratt, G., Jenner, M. W., Owen, R. G., Snowden, J. A., Ashcroft, J., Yong, K., Feyler, S., Morgan, G. J., Cavenagh, J. D., Cook, G., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.12926 · Cited by 25
Recent advances in understanding multiple myeloma
Dhakal, B., Girnius, S. K., & Hari, P. (2016) · F1000Research · doi:10.12688/f1000research.8777.1 · Cited by 25
Self-citationKidney Transplantation for Kidney Failure Due to Multiple Myeloma: Case Reports
Le, T. X., Wolf, J. L., Peralta, C. A., & Webber, A. B. (2017) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.12.023 · Cited by 24
Heavy+light chain monitoring correlates with clinical outcome in multiple myeloma patients
Michallet, M., Chapuis‐Cellier, C., Dejoie, T., Lombard, C., Caillon, H., Sobh, M. A. K., Moreau, P., Attal, M., & Avet‐Loiseau, H. (2017) · Leukemia · doi:10.1038/leu.2017.209 · Cited by 25
Quality of life outcomes in multiple myeloma patients: a summary of recent clinical trials
Martino, M. V., Rossi, M., Ferreri, A., Loteta, B., Morabito, A., Moscato, T., Console, G., Innao, V., Naso, V., Provenzano, P. F., et al. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1634541 · Cited by 24
Stem-cell transplantation in multiple myeloma: how far have we come?
Soekojo, C. Y., & Kumar, S. K. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620719888111 · Cited by 24
Newly Diagnosed Myeloma in 2020
Moreau, P., Touzeau, C., Vij, R., Goldsmith, S. R., & Rosko, A. E. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280221 · Cited by 24
Self-citationRosenberg, A. S., Brunson, A. M., Tuscano, J. M., Jonas, B. A., Hoeg, R. T., Wun, T., & Keegan, T. H. M. (2021) · Blood Cancer Journal · doi:10.1038/s41408-020-00400-4 · Cited by 24
Gertz, M. A., Terpos, E., Dispenzieri, A. A., Kumar, S. K., Shah, R., Orlowski, R. Z., Kastritis, E., Dimopoulos, M. A., & Shah, J. J. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.970543 · Cited by 24
Zou, Y., Sheng, Z., Niu, S., Wang, H., Yu, J., & Xu, J. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.774393 · Cited by 24
Management of Relapsed Multiple Myeloma after Autologous Stem Cell Transplant
Holstein, S. A., Richardson, P. G. G., Laubach, J. P., & McCarthy, P. L. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.12.026 · Cited by 23
Self-citationAn overview of hematopoietic stem cell transplantation related thrombotic complications
Şahin, U., Atilla, P. A., Atilla, E., Toprak, S. K., & Demirer, T. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.09.004 · Cited by 23
Lemieux, C., Muffly, L. S., Iberri, D. J., Craig, J. K., Johnston, L., Lowsky, R., Shiraz, P., Rezvani, A. R., Frank, M. J., Weng, W., et al. (2021) · Bone Marrow Transplantation · doi:10.1038/s41409-021-01371-1 · Cited by 25
Autologous hematopoietic cell transplantation: An update for clinicians
Hamadani, M. (2014) · Annals of Medicine · doi:10.3109/07853890.2014.952662 · Cited by 23
Bhatt, V. R., Loberiza, F. R., Jing, H., Bociek, R. G., Bierman, P. J., Maness, L. J., Vose, J. M., Armitage, J. O., & Akhtari, M. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2015.02.024 · Cited by 23
Vaccination of multiple myeloma: Current strategies and future prospects
Allegra, A., Penna, G., Innao, V., Greve, B., Maisano, V., Russo, S., & Musolino, C. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.06.003 · Cited by 23
Cornell, R. F., D’Souza, A., Kassim, A. A., Costa, L. J., Innis-Shelton, R. D., Zhang, M., Huang, J., Abidi, M. H., Aiello, J., Akpek, G., et al. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.11.011 · Cited by 23
Self-citationLiu, A., Li, S., Donnenberg, V. S., Fu, J., Gollin, S. M., Ma, H., Lu, C., Stolz, D. B., Mapara, M. Y., Monaghan, S. A., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.188227 · Cited by 25
Raje, N. S., Hideshima, T., Yee, A. J., & Anderson, K. C. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm122 · Cited by 23
Self-citationLenalidomide-Associated Secondary B-Lymphoblastic Leukemia/Lymphoma—A Unique Entity
Germans, S. K., Kulak, O., Koduru, P. R. K., Oliver, D., Gagan, J., Patel, P. A., Anderson, L. D., Fuda, F. S., Chen, W., & Jaso, J. M. (2020) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqaa109 · Cited by 22
Sanchorawala, V., Hoering, A., Seldin, D. C., Finn, K. T., Fennessey, S. A., Sexton, R. E., Mattar, B. I., Safah, H. F., Holmberg, L., Dean, R. M., et al. (2013) · Bone Marrow Transplantation · doi:10.1038/bmt.2013.98 · Cited by 22
Martino, M. V., Olivieri, A., Offidani, M., Vigna, E., Moscato, T., Fedele, R., Montanari, M., Console, G., Gentile, M., Messina, G., et al. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.788643 · Cited by 22
Bortezomib and lenalidomide as front-line therapy for multiple myeloma
Zou, Y., Lin, M., Sheng, Z., & Niu, S. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.847935 · Cited by 22
Minimal Residual Disease by Next-Generation Sequencing: Pros and Cons
Avet‐Loiseau, H. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_159088 · Cited by 22
Current Review on High-Risk Multiple Myeloma
Chan, H. S. H., Chen, C. I., & Reece, D. E. (2017) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-017-0368-z · Cited by 22
Diagnosis and management of neuropathies associated with plasma cell dyscrasias
E, E. R. P., Marks, D. K., & Raza, S. (2017) · Hematological Oncology · doi:10.1002/hon.2417 · Cited by 23
Immune Checkpoint Inhibition in Hodgkin Lymphoma
Moy, R. H., & Younes, A. (2018) · HemaSphere · doi:10.1097/hs9.0000000000000020 · Cited by 22
Soiffer, R. J., & Chen, Y. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017009894 · Cited by 22
Second Primary Malignancy Risk in Multiple Myeloma from 1975 to 2018
Wang, J., Lv, C., Zhou, M., Xu, J., Chen, B., & Wan, Y. (2022) · Cancers · doi:10.3390/cancers14194919 · Cited by 22
Risk stratification in multiple myeloma, part 1: characterization of high-risk disease.
Biran, N., Jagannath, S., & Chari, A. (2013) · PubMed · Cited by 22
Giri, S., Dhakal, B., Callander, N. S., Medvedova, E., Godby, K. N., Dholaria, B., Bal, S., Ravi, G., Chhabra, S., Silbermann, R. W., et al. (2025) · Blood · doi:10.1182/blood.2024027674 · Cited by 23
Self-citationFall, D. J., Stessman, H. A. F., Patel, S. S., Sachs, Z., Ness, B. G. V., Baughn, L. B., & Linden, M. A. (2014) · Journal of Cancer · doi:10.7150/jca.9864 · Cited by 21
Efficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-Analysis
Wang, X., Li, Y., & Yan, X. (2016) · BioMed Research International · doi:10.1155/2016/6848902 · Cited by 21
Nadiminti, K. V. G., Sidiqi, M. H., Meleveedu, K. S., Alkhateeb, H. B., Hogan, W. J., Litzow, M. R., Patnaik, M. M., Kumar, S. K., Gertz, M. A., Chen, D., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00454-y · Cited by 21
Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms
Guo, H., Yang, J., Wang, H., Liu, X., Liu, Y., & Zhou, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1017990 · Cited by 21
Miyamoto, T., Yoshimoto, G., Kamimura, T., Muta, T., Takashima, S., Ito, Y., Shiratsuchi, M., Choi, I., Kato, K., Takenaka, K., et al. (2013) · International Journal of Hematology · doi:10.1007/s12185-013-1402-0 · Cited by 21
Mark, T. M., Coleman, M., & Niesvizky, R. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.02.008 · Cited by 21
Immunomodulator drug-based therapy in myeloma and the occurrence of thrombosis
Boyle, E. M., Fouquet, G., Manier, S., Gauthier, J., Noel, M. P., Borie, C., Facon, T. T. F., Elalamy, I., & Leleu, X. P. (2012) · Expert Review of Hematology · doi:10.1586/ehm.12.52 · Cited by 21
Perspectives in the treatment of multiple myeloma
Gentile, M., Recchia, A. G., Mazzone, C., Lucia, E., Vigna, E., & Morabito, F. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.799132 · Cited by 22
Giannopoulos, K., Jamroziak, K., Usnarska‐Zubkiewicz, L., Dytfeld, D., Jurczyszyn, A. J., Walewski, J. A., Lech‐Marańda, E., Walter‐Croneck, A., Pieńkowska‐Grela, B., Wróbel, T., et al. (2018) · Acta Haematologica Polonica · doi:10.2478/ahp-2018-0024 · Cited by 22
Gupta, N., Labotka, R., Liu, G., Hui, A., & Venkatakrishnan, K. (2016) · Investigational New Drugs · doi:10.1007/s10637-016-0346-7 · Cited by 21
Costa, L. J., Landau, H. J., Chhabra, S., Hari, P., Innis-Shelton, R. D., Godby, K. N., Hamadani, M., Tamari, R., Anderton, K., Dixon, P. M., et al. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.01.036 · Cited by 21
Self-citationJackson, G. H., Galinsky, J., Alderson, D., D’Souza, V., Buchanan, V., Dhanasiri, S., & Walker, S. (2019) · European Journal Of Haematology · doi:10.1111/ejh.13298 · Cited by 21
Targeted Therapies for Multiple Myeloma
Leow, C. C.-Y., & Low, M. S. Y. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11050334 · Cited by 21
Efficacy and Safety of Lenalidomide in the Treatment of Multiple Myeloma
Qiao, S.-K., Guo, X., Ren, J., & Ren, H. (2015) · Chinese Medical Journal · doi:10.4103/0366-6999.156134 · Cited by 23
Eshaghian, S., & Berenson, J. R. (2012) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0b013e3283565c56 · Cited by 20
Advances in multiple myeloma therapy during two past decades
Špıčka, I. (2014) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2014.05.005 · Cited by 20
Besson, L., Charrier, E., Karlin, L., Allatif, O., Marçais, A., Rouzaire, P., Belmont, L., Attal, M., Lombard, C., Salles, G. A., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00704 · Cited by 20
Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma
Sborov, D. W., Benson, D. M., Williams, N., Huang, Y., Bowers, M. A., Humphries, K., Efebera, Y. A., Devine, S. M., & Hofmeister, C. C. (2015) · British Journal of Haematology · doi:10.1111/bjh.13527 · Cited by 20
Self-citationWaal, E. G. M. D., de Munck, L., Hoogendoorn, M., Woolthuis, G., van der Velden, A. W. G., Tromp, Y., Vellenga, E., & Hovenga, S. (2015) · British Journal of Haematology · doi:10.1111/bjh.13653 · Cited by 20
Metadata
- Authors
- McCarthy, P. L., Owzar, K., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Richardson, P. G., Giralt, S., Stadtmauer, E. A., Weisdorf, D. J., Vij, R., Moreb, J. S., Callander, N. S., Van Besien, K., Gentile, T., Isola, L., Maziarz, R. T., Gabriel, D. A., Bashey, A., Landau, H., Martin, T., Qazilbash, M. H., Levitan, D., McClune, B., Schlossman, R., Hars, V., Postiglione, J., Jiang, C., Bennett, E., Barry, S., Bressler, L., Kelly, M., Seiler, M., Rosenbaum, C., Hari, P., Pasquini, M. C., Horowitz, M. M., Shea, T. C., Devine, S. M., Anderson, K. C., & Linker, C.
- Affiliations
- Roswell Park Comprehensive Cancer Center (US)
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- Duke University (US)
- Memorial Sloan Kettering Cancer Center (US)
- Dana-Farber Cancer Institute (US)
- Abramson Cancer Center (US)
- University of Minnesota Medical Center (US)
- Washington University in St. Louis (US)
- University of Florida (US)
- University of Wisconsin–Madison (US)
- State University of New York (US)
- Mount Sinai Hospital (US)
- Oregon Health & Science University (US)
- University of North Carolina at Chapel Hill (US)
- BMT Group (United States) (US)
- University of California, San Francisco (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of Chicago (US)
- University of Chicago Medical Center (US)
- Medical College of Wisconsin (US)
- ORCID
- McCarthy, Philip L.
- Owzar, Kouros
- Hofmeister, Craig C.
- Hassoun, Hani
- Richardson, Paul G.
- Giralt, Sergio
- Stadtmauer, Edward A.
- Weisdorf, Daniel J.
- Vij, Ravi
- Moreb, Jan S.
- Callander, Natalie Scott
- Gentile, Teresa
- Isola, Luis
- Maziarz, Richard T.
- Landau, Heather
- Martin, Thomas
- Qazilbash, Muzaffar H.
- McClune, Brian
- Jiang, Chen
- Bennett, Elizabeth
- Kelly, Michael
- Rosenbaum, Cara
- Hari, Parameswaran
- Pasquini, Marcelo C.
- Horowitz, Mary M.
- Devine, Steven M.
- Anderson, Kenneth C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-05-10
- Volume
- 366
- Issue
- 19
- Pages
- 1770-1781
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3744390
- OpenAlex
- W2125721471
- Semantic Scholar
- b20a8f57aae32a45c1804976b107b4ba1609688f
- Cited by
- 1,147
- References
- 42
- Citations by year
- 2026: 28 · 2025: 30 · 2024: 40 · 2023: 40 · 2022: 51 · 2021: 74 · 2020: 81 · 2019: 70 · 2018: 82 · 2017: 104 · 2016: 107 · 2015: 100 · 2014: 113 · 2013: 144 · 2012: 81
- FWCI
- 93.26
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- Funders
- National Heart, Lung, and Blood Institute (U10HL069334, U10HL069301, U10HL069348, U10HL109526, U01HL069294, U10HL069294, U10HL069330, U10HL069315, U10HL069290, U10HL069286, UG1HL069286, UG1HL069315)
- National Cancer Institute (U10CA033601, P50CA100707, U10CA031946, U10CA021115, U24CA076518)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- lenalidomide, multiple myeloma, autologous stem cell transplantation, maintenance therapy, time to progression, overall survival, secondary malignancies, hematologic adverse events, drug toxicity
- MeSH terms
- Lenalidomide, Adult, Aged, Antineoplastic Agents, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Middle Aged, Multiple Myeloma, Thalidomide, Neoplasms, Second Primary, Disease-Free Survival, Stem Cell Transplantation, Maintenance Chemotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
